Skip to main content
Premium Trial:

Request an Annual Quote

Cedars-Sinai Joins GenomeDx-Led Prostate Cancer Genomic Data Sharing Platform

NEW YORK (GenomeWeb) – GenomeDx Biosciences today announced a partnership with Cedars-Sinai Medical Center on the Decipher Genomics Resource Information Database (GRID).

Decipher GRID is a clinical genomics data sharing program aimed to provide clinicians with information on prostate cancer and other urologic cancers. Under the terms of the agreement, Cedars-Sinai will treat prostate cancer patients using the platform as well as use the firm's Decipher Prostate Cancer Classifier test to aid treatment decisions. GenomeDx will conduct whole-genome profiling for patients included in the program and match those data to prospectively collected clinical outcomes for patients treated at major cancer centers.

Financial and other details of the agreement were not disclosed.

GRID is the largest accessible genomic expression database for urologic cancers, GenomeDx said in a statement. "Through partnerships with groups like Cedars-Sinai we can marry the power of genomic information with prospective clinical outcomes for patients," GenomeDx CEO Doug Dolginow said.

San Diego- and Vancouver, Canada-based GenomeDx launched Decipher GRID in May, initially partnering with Thomas Jefferson University's Sidney Kimmel Cancer Center.

In 2014, Cedars-Sinai tapped N-of-One to provide database services.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.